Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 5/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.72 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420925 | 1.00 | TRPM2 (0.74) | TRPM2LTB4RTRPA1EGFRSERPINE1 | |
| SCHEMBL8060454 | 0.92 | EGFR (0.75) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL8060457 | 0.92 | EGFR (0.75) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL8065880 | 0.91 | TRPA1 (0.75) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL8065883 | 0.91 | TRPA1 (0.75) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL417073 | 0.90 | EGFR (0.62) | TRPM2LTB4RTRPA1EGFRSERPINE1 | |
| SCHEMBL417074 | 0.90 | EGFR (0.62) | TRPM2LTB4RTRPA1EGFRSERPINE1 | |
| SCHEMBL418156 | 0.88 | ALDH1A1 (0.59) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL418157 | 0.88 | ALDH1A1 (0.59) | TRPM2LTB4RTRPA1EGFRMEN1 | |
| SCHEMBL2271618 | 0.86 | TRPA1 (0.73) | TRPM2LTB4RTRPA1EGFRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114831977-A | Application of benzoic acid derivatives as TRPM2 protein inhibitors | 北京大学 | 2022-08-02 | — | — | CN | claimed |
| CN-114831977-B | Application of benzoic acid derivative as TRPM2 protein inhibitor | 北京大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-114831977-A | Application of benzoic acid derivatives as TRPM2 protein inhibitors | 北京大学 | 2022-08-02 | — | — | CN | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2990057-B1 | PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT | RENASCIENCE CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | TRPM2 4652/4885LTB4R 2382/4885TRPA1 4798/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | TRPM2 3818/4885LTB4R 885/4885TRPA1 4141/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | TRPM2 3818/4885LTB4R 885/4885TRPA1 4141/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | TRPM2 4660/4885LTB4R 2350/4885TRPA1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.